SCHEMBL16620091

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

	Compound	similarity	top predicted	shared targets
	SCHEMBL16628320	0.94	ACHE (0.35)	FGF2SELP
	SCHEMBL18133691	0.94	FGF2 (0.34)	FGF2CLEC4M
	SCHEMBL16620496	0.91	FGF2 (0.32)	FGF2
	SCHEMBL18053515	0.89	KDM4E (0.34)	FGF2
	SCHEMBL19860840	0.89	ACHE (0.33)	FGF2
	SCHEMBL16628193	0.89	ACHE (0.33)	FGF2
	SCHEMBL16621137	0.89	ACHE (0.33)	FGF2
	SCHEMBL19860890	0.89	ACHE (0.33)	FGF2
	SCHEMBL16628215	0.89	ACHE (0.33)	FGF2
	SCHEMBL16621037	0.89	ACHE (0.33)	FGF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.